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Abstract
Background: Autoantibodies to the catalytic domain of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) have
been recently identified as a new family of autoantibodies involved in rheumatoid arthritis (RA). The objective of this study
was to determine antibody responses to the catalytic domain of BRAF in RA and other autoimmune diseases. The
association between RA-related clinical indices and these antibodies was also assessed.
Methodology/Principal Findings: The presence of autoantibodies to the catalytic domain of BRAF (anti-BRAF) or to peptide
P25 (amino acids 656–675 of the catalytic domain of BRAF; anti-P25) was determined in serum samples from patients with
RA, primary Sjo ¨gren’s syndrome (pSS), systemic lupus erythematosus (SLE), and healthy controls by using indirect enzyme-
linked immunosorbent assays (ELISAs) based on the recombinant catalytic domain of BRAF or a synthesized peptide,
respectively. Associations of anti-BRAF or anti-P25 with disease variables of RA patients were also evaluated. Our results
show that the BRAF-specific antibodies anti-BRAF and anti-P25 are equally present in RA, pSS, and SLE patients. However,
the erythrocyte sedimentation rate (ESR) used to detect inflammation was significantly different between patients with and
without BRAF-specific antibodies. The anti-BRAF-positive patients were found to have prolonged disease, and active disease
occurred more frequently in anti-P25-positive patients than in anti-P25-negative patients. A weak but significant correlation
between anti-P25 levels and ESRs was observed (r=0.319, p=0.004).
Conclusions/Significance: The antibody response against the catalytic domain of BRAF is not specific for RA, but the higher
titers of BRAF-specific antibodies may be associated with increased inflammation in RA.
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Introduction
Autoimmune diseases occur when the body’s immune system
attacks self-antigens. This induces prolonged inflammation and
subsequent tissue destruction. Rheumatoid arthritis (RA), a common
systemic autoimmune disease of unknown etiology, is characterized
bychronically inflamed synovial joints and subsequent destruction of
cartilage and bones. Despite decades of research, the pathogenesis of
RAisstillunresolved.OneofthehallmarksofRAisthepresenceofa
broad spectrum of autoantibodies against aberrantly expressed
autoantigens. The discovery of autoantibodies to citrullinated
proteins such as fibrin and vimentin in patients with RA was one
of the most important findings in rheumatology research [1].
Advances in protein array technologies have enabled large-scale
analysis of proteins to identify significant biomarkers that contribute
to disease pathogenesis. A recently published paper describing 8,268
protein arrays using RA sera indicates that the catalytic domain of v-
raf murine sarcoma viral oncogene homologue B1 (BRAF) is a new
autoantigen for RA [2].
BRAF is a serine-threonine kinase involved in the mitogen-
activated protein kinase (MAPK) pathways that regulate cell
survival, proliferation, differentiation, cytokine generation, and
metalloproteinase production [3]. BRAF somatic missense muta-
tions are reported in 66% of malignant melanomas and at a lower
frequency in a wide range of other human cancers [4]. A mutated
BRAF gene with a single amino acid substitution (BRAF V600E)
results in higher kinase activity. Thus, the resulting BRAF protein,
which has protective activity against Raf kinase inhibitors, has
been considered as a potential target for tumor therapy [5]. On
the other hand, the MAPK pathways are implicated in the
pathogenesis of certain inflammatory autoimmune diseases such as
RA via their regulatory effects on the production of cytokines or
metalloproteinases [6–9]. Recent data show that serum antibodies
to the catalytic domain of BRAF (anti-BRAF) can activate BRAF
in vitro. This indicates that anti-BRAF may play a role in
inflammation in RA through activation of the MAPK pathway
[10]. The results of peptide array analysis indicate that the
antibody response to P25 (amino acids 656–675 of the catalytic
domain of BRAF) is specific to RA. However, antibodies to
peptide P25 (anti-P25) were defined as specific markers for RA,
based on comparison to small patient cohorts with ankylosing
spondylitis (AS) and psoriasis arthritis (PsA), rather than to patients
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the antibody responses to the catalytic domain of wild-type BRAF
and peptide P25 in Chinese patients with RA, primary Sjo ¨gren’s
syndrome (pSS), and systemic lupus erythematosus (SLE) by
indirect enzyme-linked immunosorbent assays (ELISAs) and
investigated the possible associations between these antibodies
and the disease indicators of RA.
Materials and Methods
Ethics statement
Written informed consent was not obtained because of the
nature of the study design, which utilized serum samples taken
after routine tests. All subjects recruited in this study were
informed of the nature of the project and verbal informed consent
was obtained from each patient, This was recorded by the
physician who explained the study procedure. The study protocol
and verbal consent document were approved by the Ethics
Committee of the National Center for Clinical Laboratories,
where the study was performed.
DNA constructs
The DNA segment corresponding to the catalytic domain of
wild-type BRAF (amino acids 416–766) was generated by PCR
using specific primers carrying restriction sites. The pEF-myc-
BRAF plasmid containing full-length human BRAF cDNA, was
kindly provided by Dr. Richard Marais (Institute of Cancer
Research, London, United Kingdom). Enzyme-restricted PCR
products were ligated into the multiple cloning sites of the pET28b
expression vector by T4 DNA ligase. The desired clones were
confirmed by sequencing.
Protein expression and purification
The recombinant plasmid carrying the catalytic domain of wild-
type BRAF (pET28b-BRAF) was transformed into Escherichia coli
BL-21(DE3). Further, a 66His-tagged protein was expressed with
induction by 0.1 mM isopropyl-b-D-thiogalactoside (IPTG) for
4 h at 37uC. Bacterial pellets from a total of 1 L of culture were
resuspended in 10 mL lysis buffer (50 mM Tris-Cl, 100 mM
NaCl, 5 mM EDTA, 1% NaN3, 0.5% Triton X-100, 5 mM DTT,
pH 8.0). After the suspension was prepared, lysozyme (Sigma-
Aldrich, St. Louis, MO, USA) was added to a final concentration
of 0.2 mg/mL, followed by incubation at room temperature (RT)
for 30 min. The cells were further disrupted by sonication on ice
for 10 min (on for 5 s, off for 5 s). The homogenate was then
centrifuged at 4uC for 30 min at 6000 g. The supernatant was
discarded, and the inclusion bodies were collected. The collected
precipitates were resuspended in 10 mL washing buffer (100 mM
Tris-Cl, 5 mM EDTA, 5 mM DTT, 2 M urea, 2% Triton X-100,
pH 8.0) and incubated at RT for 20 min. The inclusion bodies
were then recovered by centrifugation at 4uC for 30 min at
8000 g. The above washing step was repeated twice, the inclusion
bodies were dissolved in binding buffer (20 mM sodium
phosphate, 0.5 M NaCl, 40 mM imidazole, 1.5% Triton X-100,
4 mM DTT, 6 M guanidine-HCl, pH 8.0), and the recombinant
protein was further purified by affinity chromatography on a Ni-
Sepharose Fast flow (FF) column (GE Healthcare, Uppsala,
Sweden). The His-tagged protein was eluted with a linear
concentration gradient of imidazole from 40 to 400 mM. The
fractions containing the target protein were pooled, dialyzed to
remove imidazole, and stored in the presence of 6 M guanidine-
HCl at 220uC. The protein concentration was determined by a
standard bicinchoninic (BCA) protein assay (Pierce, Rockford,
USA). To evaluate the size and purity of the recombinant protein,
samples were denatured in SDS loading buffer (25 mM Tris-HCl,
pH 6.8, 5% b-mercaptoethanol, 2% SDS, 50% glycerol),
separated on a 10% polyacrylamide gel, and stained with
Coomassie blue.
Serum samples
Serum samples were obtained from a previously described RA
cohort that fulfilled the American College of Rheumatology (ACR)
criteria for RA [11,12] and included 101 patients in the final study.
For comparison, samples from 250 subjects with other autoim-
mune diseases were tested, including samples obtained from 132
patients with pSS and samples obtained from 118 patients with
SLE. Healthy controls (140) were also included to determine the
cutoff value for positivity. Serum samples were stored at 280uC
until analysis. The following data were collected from RA patients:
gender, age, disease duration, rheumatoid factor (RF), anti-cyclic
citrullinated peptide antibodies (anti-CCP), erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), and disease status.
Recent-onset RA was defined as RA with disease duration of less
than 2 years. RF and CRP levels were determined by an
immunonephelometric method. Values .7.9 mg/L for CRP and
.20 IU/mL for RF were considered positive. Anti-CCP antibod-
ies were assessed with a commercial ELISA kit (Immunoscan
CCPlus, Euro-Diagnostica, Malmo, Sweden) according to the
manufacturer’s recommendations. The cutoff value for a positive
reaction was set at 25 U/mL, as suggested by the manufacturer.
The ESR was measured by Westergren’s method; values
#15 mm/h for men and #20 mm/h for women were considered
normal. Active RA was defined as described previously [12]. The
basic characteristics of the RA cohort are described in Table 1.
Table 1. Demographic data and disease indicators of 101
patients with RA.
Number Description
Females/Males 101 81/20
Age, years 101 47.3613.8
Disease duration, years 97 5 (0.1–50)
Recent onset 35 1 (0.1–2)
Prolonged 62 8 (3–50)
RF 97
RF-positive 83 82.2%
Anti-CCP(U/mL) 101 353 (16–5477)
Anti-CCP-positive 74 811 (25–5477)
ESR, mm/h 81 56633
Normal 14 1265
Elevated 67 66628
CRP 62
Elevated 25 40.3%
Disease status 101
Active disease 47 46.5%
RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies; ESR:
erythrocyte sedimentation rate; CRP: C-reactive protein.
Categorical variables are given as %; normally distributed data are given in
mean 6 SD; other continuous variables are given in median (range).
doi:10.1371/journal.pone.0028975.t001
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Specific antibodies to the recombinant catalytic domain of wild-
type BRAF were identified in sera by an indirect ELISA. To
conduct the assay, 100 mL of the recombinant catalytic domain of
BRAF (2.5 mg/mL) was incubated in an ELISA plate (Nunc
Maxisorp, Roskilde, Denmark) at 4uC overnight. Microwells were
then washed with phosphate-buffered saline (PBS: 0.01 M,
pH 7.4) with 0.05% Tween-20 (PBST). Unbound sites were
blocked by incubation with 200 mL 20% newborn calf serum
(NCS) in PBS at 37uC for 1.5 h. Sera were diluted 1:200 in
blocking buffer and aliquots of 100 mL were added to the wells.
Wells coated with bovine serum albumin (BSA) were prepared for
each sample, to assess non-specific binding. After incubation at
37uC for 1 h, plates were washed 3 times with PBST.
Subsequently, the captured antibodies were detected by a
horseradish peroxidase (HRP)-conjugated goat anti-human IgG
(1:10000) (Sigma), which was diluted with 20% NCS in PBST
(100 mL/well). After incubation at 37uC for 30 min, wells were
washed 5 times with PBST. Color was developed by application of
100 mL of tetramethylbenzidine (Sigma) at 37uC for 20 min. The
reaction was stopped by addition of 0.5 M sulfuric acid, and the
optical density at 450 nm (OD450), with 620 nm as the correction
wavelength, was obtained using an ELISA plate reader (Labsys-
tems, Finland).
Each sample was assayed in duplicate. A positive serum sample
was included in each assay and used to correct for inter-assay
variations. Results were expressed as arbitrary units (AU)
calculated as ([OD450 of sample2OD450 of the non-specific
binding of the sample]/[OD450 of the positive control2OD450 of
the non-specific binding of the positive control])6100.
Detection of IgG autoantibodies to P25 by ELISA
To test patient reactivity to peptide P25 (YSNINNRD-
QIIFMVGRGYLS, a peptide encompassing amino acids 656–
675 of the catalytic domain of BRAF), an indirect ELISA for
quantifying IgG autoantibodies to P25 was conducted. Serum
samples from RA, pSS, and SLE patients were included in the
assay. Eighty-nine of 140 healthy controls were also included to
evaluate the cutoff value. To efficiently coat microwells with the
peptide, BSA-conjugated P25, synthesized by the Chinese Peptide
Company (Hangzhou, Zhejiang, China) via the solid-phase
method, was used as an antigen. The purity of the conjugate
was greater than 95%. Plates were coated overnight with BSA-P25
at a concentration of 5 mg/mL. After blocking unbound sites, the
serum samples were diluted 1:100 and incubated with the plates at
RT for 1 h. Wells coated with BSA were prepared for each sample
to determine non-specific binding. After washing, HRP-conjugat-
ed goat anti-human IgG was added and incubated at RT for 1 h.
The plate was read at an OD of 450 nm, with 620 nm as the
correction wavelength, using an ELISA plate reader.
Each sample was tested in duplicate. A positive serum sample
was included in each assay and used to correct for inter-assay
variations. Data was processed as described in the anti-BRAF
ELISA procedure.
Statistical analyses
Statistical analyses were performed using SPSS 13.0 for
Windows. For normally distributed data, results are expressed as
the mean and standard deviation (mean (SD)); differences between
groups were assessed by t-tests. For data not distributed normally,
results are expressed as the median (range); differences between
groups were analyzed using the Mann-Whitney U-test and
correlations were determined by computing Spearman rank
correlation coefficients. Pearson’s 2-tailed x
2 test or Fisher’s exact
test were used to compare proportions. P values,0.05 were
considered statistically significant.
Results
Expression and purification of recombinant protein
The recombinant catalytic domain of wild-type BRAF was
expressed from pET28b-BRAF-transformed bacteria under IPTG
induction. The expressed protein was within insoluble inclusion
bodies. To obtain pure antigens, a protocol for inclusion-body
extraction followed by affinity chromatography was implemented.
Following extraction, recombinant proteins were predominantly
identified in collected precipitates, but remained contaminated
with a small quantity of host proteins. For further purification,
precipitates were solubilized in 6 M guanidine-HCl and purified
using nickel affinity chromatography under denaturing conditions.
The His-tagged recombinant proteins were eluted with a gradient
of increasing imidazole concentration and were detected as a
single protein band at a molecular weight of approximately 40 kD
on a 10% SDS-PAGE gel (Figure 1). The protein concentration
was 1.5 mg/mL as determined by BCA.
Prevalence of antibody responses to BRAF in diseases
and controls
The distribution of BRAF-specific antibodies in RA, pSS, SLE
and healthy control patients is shown in Figure 2. The cutoff value
for positivity was set as 2 SD above the mean AU of the healthy
controls. The prevalence of anti-BRAF and anti-P25 is listed in
Table 2. There was no significant difference in anti-BRAF or anti-
P25 prevalence among RA, pSS, and SLE patients. However, the
prevalence of BRAF specific antibodies was significantly higher in
disease samples (RA, pSS, and SLE) than in the healthy controls
(p=0.001 for all). 8 serum samples of RA patients were identified
Figure 1. Analysis of the recombinant catalytic domain of BRAF
by SDS-PAGE. Samples were separated by electrophoresis on
polyacrylamide gels and stained with Coomassie blue. M: molecular
mass marker proteins. Lane 1: BL21-(DE3) cells carrying pET28b-BRAF
plasmid induced by 0.1 mM IPTG for 4 h at 37uC. Lane 2: inclusion
bodies after extraction. Lane 3: 66 His-tagged proteins eluted with
imidazole. The weight of the molecular mass markers is indicated on
the left side of the figure.
doi:10.1371/journal.pone.0028975.g001
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RA samples were identified as anti-P25 negative and anti-BRAF
positive. A similar tendency was also observed among pSS and
SLE patients.
Associations between BRAF-specific antibodies and
disease indicators in RA patients
Of the 101 RA patients, 21 (20.8%) and 19 (18.8%) were
identified as positive for anti-BRAF and anti-P25, respectively.
Patients with BRAF-specific antibodies had significantly higher
ESRs than patients without these antibodies (p=0.040 for anti-
BRAF and p=0.030 for anti-P25). Patients with prolonged disease
had a significantly higher prevalence of anti-BRAF (18/62) than
patients with recent-onset disease (2/35) (p=0.006). Furthermore,
active disease occurred more frequently in anti-P25-positive
patients than in anti-P25-negative patients (p=0.034). Compar-
isons of disease indicators between patients with and without
BRAF-specific antibodies are shown in Table 3. A weak but
significant correlation was found between anti-P25 antibodies and
ESRs in the RA patients (r=0.319, p=0.004) (Figure 3).
Discussion
Autoantibodies to BRAF, in particular anti-P25 antibodies,
have been recently identified as specific markers for RA. However,
this suggestion is based on the evidence that anti-P25 is specifically
detected in RA patients comparing with AS and PsA. In this
report, we developed indirect ELISAs on the basis of the
recombinant catalytic domain of BRAF or the synthesized peptide
P25 and determined the prevalence of autoantibodies to BRAF in
patients with RA, pSS, or SLE and in healthy controls.
Associations between anti-BRAF or anti-P25 and disease variables
were investigated in the RA cohort. Our results indicate that
neither anti-BRAF nor anti-P25 autoantibodies are specific
markers for RA. Nevertheless, the associations between anti-
BRAF or anti-P25 and disease variables suggest potential
involvement of these antibodies in inflammation in RA patients.
Protein arrays have been used to identify the catalytic domain of
BRAF as a new autoantigen involved in RA [2]. Recently,
Charpin et al. [10] further identified the peptide targets of anti-
BRAF by using 40 overlapping 20-mers encompassing the entire
catalytic domain of BRAF. It was shown that 1 peptide, P25
(amino acids 656–675), is specifically recognized by anti-BRAF
from serum of RA patients [10]. In the present study, we detected
the presence of anti-BRAF and anti-P25 in the serum of RA
patients by developing indirect ELISAs on the basis of the
recombinant catalytic domain of BRAF in its denatured form and
a synthesized peptide P25, respectively. Recombinant proteins
dissolved in denaturant have been successfully used to coat
antigens in ELISAs. This ensures the validity of our assays for anti-
BRAF [13–14]. We unexpectedly observed a considerable
prevalence of anti-BRAF and anti-P25 in pSS patients and SLE
patients. In the previous 2 studies investigating anti-BRAF in RA
patients, the disease controls were AS patients and/or PsA
patients, and cohorts used were relatively small [2,10]. Thus, the
involvement of autoantibodies to BRAF in other autoimmune
Figure 2. Distribution of BRAF-specific antibodies in diseases and controls. BRAF-specific antibodies were detected in patients with
rheumatoid arthritis (RA, n=101), primary Sjo ¨gren’s syndrome (pSS, n=132), systemic lupus erythematosus (SLE, n=118), and healthy controls (HC,
n=140 for anti-BRAF and n=89 for anti-P25) using indirect ELISAs based on the recombinant catalytic domain of BRAF (A) or a synthesized peptide
(B). Antibody titers were expressed as arbitrary units (AU). The cutoff value for positivity was set as 2 SD above the mean AU of the healthy controls
(dashed line).
doi:10.1371/journal.pone.0028975.g002
Table 2. Prevalence of BRAF specific antibodies in the test samples.
Disease anti-BRAF positive (%) anti-P25 positive (%)
anti-BRAF positive & anti-p25
negative
anti-BRAF negative & anti-p25
positive
RA 21/101 (20.8) 19/101 (18.8) 10 8
SLE 24/118 (20.3) 25/118 (21.2) 9 10
pSS 27/135 (20.5) 24/132 (18.2) 12 9
HC 9/140 (6.4) 2/89 (2.2) 3 0
Since the anti-p25 was not test in all the patients and health controls, the results we list in the last two columns were from the participants that both anti-BRAF and anti-
p25 were tested.
doi:10.1371/journal.pone.0028975.t002
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specific antibodies in larger cohorts of patients with pSS and SLE.
The prevalence of anti-BRAF (catalytic domain) or anti-P25 in
these 3 diseases (RA, pSS, and SLE) is similar, This suggests that,
to some extent, the production of autoantibodies to BRAF might
be a common event in systemic autoimmune disorders. There is
evidence that different subsets of autoantibodies have different
cytokine requirements [15]. Thus, the indistinguishable prevalence
of BRAF-specific antibodies among RA, pSS, and SLE patients
raises the possibility that the cytokine environment in these
diseases is beneficial for anti-BRAF or anti-P25 production. The
repertoire of epitopes that elicit antibody responses to the catalytic
domain of BRAF might include both linear and conformational
forms. For the protein microarray, the catalytic domain of BRAF
was adhered to the glass slide under native conditions. In contrast,
in the peptide microarray, overlapping linear peptides of the
catalytic domain were used as antigens [2,10]. In our study, it is
possible that both linear and conformed epitopes of the catalytic
domain of BRAF were involved, as the process by which
recombinant BRAF was diluted with coating buffer in denaturant
may have caused refolding. Thus, some epitopes probably become
inaccessible because of partial refolding or aggregation. This
would lead to lower detection sensitivity for a specific peptide. This
might account for some samples that were identified as anti-P25
positive but anti-BRAF negative. Furthermore, the difference in
the final molar concentration of P25 adsorbed on the microwells
between the 2 ELISAs is worthy of consideration.
Multiple signal transduction pathways have been carefully
investigated in RA. For instance, NF-kB and MAPK pathways are
attractive for intervention in light of their ability to regulate many
genes involved in immune responses [16–17]. The enormous
diversity of kinases that modulate transduction mechanisms
suggests that complex and interrelated events are involved in
inflammatory disease. The end results of these pathways may exert
influences on the production of proteins such as cytokines and
matrix metalloproteinases that are implicated in the pathogenesis
of RA [18–20]. BRAF encodes a serine-threonine kinase
downstream of RAS in the MAPK pathway and transduces
regulatory signals from RAS through MAPK. Autoantibodies to
the BRAF protein have been reported in melanoma patients and
patients with RA [2,10,21]. Most recently, Charpin, et al.
demonstrated that anti-BRAF may activate phosphorylation of
MEK1 by using BRAF in vitro. This indicates possible involvement
of BRAF autoantibodies in the inflammatory responses of RA
[10]. Here, we observe a significant difference in ESRs between
RA patients with BRAF-specific antibodies and those without
these antibodies (p=0.040 for anti-BRAF and p=0.030 for anti-
P25). Furthermore, a weak but significant correlation was
identified between ESRs and anti-P25 antibody levels (r=0.319,
p=0.004). Patients with BRAF-specific antibodies are likely to
have increased ESRs compared to those without these antibodies.
Although the ESR is a non-specific marker of inflammation, ESR
values are indeed positively correlated with severe inflammation.
On the other hand, patients with prolonged disease in our study
cohort had significantly higher levels of anti-BRAF antibodies (18/
62) than patients with recent onset disease (2/35) (p=0.006). With
respect to disease status, anti-P25-positive patients had a
significantly higher risk of incurring active disease than anti-P25-
Table 3. Comparisons of disease indicators between patients with and without BRAF-specific antibodies.
Anti-BRAF catalytic domain p Anti-P25 p
Positive Negative Positive Negative
Female (%) 85.7 78.8 0.685 81.3 86.3 0.604
Age (years) 51.5612.7 46.2614.0 0.116 49.6611.6 46.7614.3 0.429
Duration (years) 7.5 (0.3–30) 4.8 (0.1–50) 0.073 5.0 (0.2–14) 5.0 (0.1–50) 0.874
Recent onset (%) 10.0 42.9 0.006 22.2 39.2 0.175
RF-positive (%) 80.0 87.0 0.661 94.4 83.5 0.456
Anti-CCP (U/mL) 46 (17–2572) 367 (16–5477) 0.490 357 (17–3799) 338 (16–5477) 0.281
Positive (%) 66.7 75.0 0.443 84.2 70.7 0.232
ESR (mm/h) 69.3631.6 52.0632.2 0.040 71.8626.3 53.0633.2 0.030
Elevated (%) 90.0 80.3 0.499 92.9 80.6 0.444
CRP elevated 33.3 42.0 0.747 44.4 39.6 1.000
Active disease (%) 42.9 47.5 0.704 68.4 41.5 0.034
RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
Categorical variables are given as %; normally distributed data are given in mean 6 SD; other continuous variables are given in median (range). Recent onset disease is
defined as disease duration of less than 2 years.
doi:10.1371/journal.pone.0028975.t003
Figure 3. Correlation of anti-P25 antibodies with ESRs in RA
patients. The correlation of anti-P25 antibodies and ESRs in 81 RA
patients was assessed by Spearman rank correlation coefficients. The
coefficient (r=0.319, p=0.004) suggests a weak but significant
association between anti-P25 antibodies and ESR values.
doi:10.1371/journal.pone.0028975.g003
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difference in the anti-BRAF status among patients with active
disease (p=0.704). This indicates that anti-P25 is more closely
correlated with RA than anti-BRAF. The ability of anti-BRAF to
activate BRAF, thus activating the MAPK pathway, may be an
appropriate explanation for the associations between anti-BRAF
and variables of inflammation or disease activity in RA. Charpin,
et al. proposed a model to explain how extracellular autoantibod-
ies to BRAF may activate intracellular BRAF [10]. In their model,
autoantibodies to BRAF enter the cells as immune complexes via
cellular uptake. It is suggested that soluble IgG immune complexes
might undergo degradation after uptake [22]. However, it remains
unclear how immune complexes formed by BRAF and anti-BRAF
antibodies resist degradation from intracellular proteinases.
A limitation of the current study is the inability to collect
additional information regarding ESR and other demographic
data for SLE and pSS patients who participated in this research as
the disease controls, which left us unable to explore the correlation
between BRAF-specific antibodies and ESRs for each patient.
Further evaluation of BRAF-specific antibodies in autoimmune
diseases and other inflammatory diseases would strengthen the
conclusions of this study.
In summary, we have observed a similar prevalence of
autoantibodies to the intact catalytic domain of wild-type BRAF
and a peptide derived from this domain in patients with RA, pSS,
and SLE. The associations of anti-BRAF and anti-P25 with disease
variables of RA suggest that BRAF-specific antibodies may
participate in the inflammatory responses involved in RA. Our
conclusion is that anti-BRAF catalytic domain antibodies and anti-
P25 antibodies are not specific markers for RA, but the higher
titers of BRAF-specific antibodies may be associated with
increased inflammation in RA. This finding is contradictory to
that of previous studies. The results presented here contribute to
our understanding of the pathogenesis of RA and provide insights
into the development of potential intervention targets for
repressing inflammation. Extensive studies on antibody responses
to BRAF in other autoimmune diseases such as pSS and SLE
might contribute to a comprehensive understanding of its role in
autoimmune disorders.
Acknowledgments
We thank Dr. Richard Marais of the Institute of Cancer Research,
London, United Kingdom, for providing the plasmid pEF-myc-BRAF.
Author Contributions
Conceived and designed the experiments: JL WL WW. Performed the
experiments: WL WW SS YS. Analyzed the data: WL WW SS YS.
Contributed reagents/materials/analysis tools: YP LW RZ KZ. Wrote the
paper: WL WW.
References
1. Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT (2007) Anti-
citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis:
evolving concepts. Crit Rev Clin Lab Sci 44: 339–363.
2. Auger I, Balandraud N, Rak J, Lambert N, Martin M, et al. (2009) New
autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with
sera from patients with RA. Ann Rheum Dis 68: 591–594.
3. Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinase: specific
messages from ubiquitous messengers. Mol Cell Biol 19: 2435–2444.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of
the BRAF gene in human cancer. Nature 417: 949–954.
5. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, et al. (2002) Results
of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase
inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther
40: 580–581.
6. Luo SF, Fang RY, Hsieh HL, Chi PL, Lin CC, et al. (2010) Involvement of
MAPKs and NF-kappaB in tumor necrosis factor alpha-induced vascular cell
adhesion molecule 1 expression in human rheumatoid arthritis synovial
fibroblasts. Arthritis Rheum 62: 105–116.
7. Schett G, Zwerina J, Firestein G (2008) The p38 mitogen-activated protein
kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 67: 909–916.
8. Thalhamer T, McGrath MA, Harnett MM (2008) MAPKs and their relevance
to arthritis and inflammation. Rheumatology (Oxford) 47: 409–414.
9. Sweeney SE, Firestein GS (2004) Signal transduction in rheumatoid arthritis.
Curr Opin Rheumatol 16: 231–237.
10. Charpin C, Martin M, Balandraud N, Roudier J, Auger I (2010) Autoantibodies
to BRAF, a new family of autoantibodies associated with rheumatoid arthritis.
Arthritis Res Ther 12: R194.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 31: 315–324.
12. Wang W, Li J (2011) Predominance of IgG1 and IgG3 subclasses of
autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis. Clin
Rheumatol 30: 563–567.
13. Yang JC, Blanton RE, King CL, Fujioka H, Aikawa M, et al. (1996)
Seroprevalence and specificity of human responses to the Plasmodium falciparum
rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein.
Infect Immun 64: 3584–3591.
14. Di Bonito P, Grasso F, Mochi S, Accardi L, Dona ` MG, et al. (2006) Serum
antibody response to Human papillomavirus (HPV) infections detected by a
novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4,
E6 and E7 proteins. Infect Agent Cancer 1: 6–14.
15. Richards HB, Satoh M, Shaw M, Libert C, Poli V, et al. (1998) Interleukin 6
dependence of anti-DNA antibody production: evidence for two pathways of
autoantibody formation in pristane-induced lupus. J Exp Med 188: 985–990.
16. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature
410: 37–40.
17. Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases.
J Clin Invest 107: 7–11.
18. Miyazawa K, Mori A, Miyata H, Akahane M, Ajisawa Y, et al. (1998)
Regulation of interleukin-1b-induced interleukin-6 gene expression in human
fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol
Chem 273: 24832–24838.
19. Lacki JK, Samborski W, Mackiewicz SH (1997) Interleukin-10 and interleukin-6
in lupus erythematosus and rheumatoid arthritis, correlations with acute phase
proteins. Clin Rheumatol 16: 275–278.
20. Westermarck J, Li SP, Kallunki T, Han J, Ka ¨ha ¨ri VM (2001) p38 mitogen-
activated protein kinase-dependent activation of protein phosphatases 1 and 2A
inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression.
Mol Cell Biol 21: 2373–2383.
21. Fensterle J, Becker JC, Potapenko T, Heimbach V, Vetter CS, et al. (2004) B-
Raf specific antibody responses in melanoma patients. BMC Cancer 4: 62–70.
22. Johansson AG, Løvdal T, Magnusson KE, Berg T, Skogh T (1996) Liver cell
uptake and degradation of soluble immunoglobulin G immune complexes in
vivo and in vitro in rats. Hepatology 24: 169–175.
Autoantibodies to BRAF Are Not Specific for RA
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28975